CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Wang, Fang ^a,b   Ye, Yanfen ^b,c   Xu, Xia ^d   Zhou, Xuehui ^d   Wang, Jinhua ^d   Chen, Xiaoxiang ^b,d,e  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d JIANGSU CANCER HOSPITAL   (China)

^e Southeast University   (China)

Author keywords

CA 125; Clinical relapse; Cytoreductive surgery; Epithelial ovarian cancer; Tumor marker

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 84874073552     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-14     Document Type: Article

References (37)

1. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2013 63 11 30 10.3322/caac.21166 23335087
2. Cancer of the ovary. Cannistra SA, N Engl J Med 2004 351 2519 2529 10.1056/NEJMra041842 15590954 (Pubitemid 39603165)
3. The NIH Consensus Conference on Ovarian Cancer: screening, treatment, and follow-up. Trimble EL, Gynecol Oncol 1994 55 1 3 10.1006/gyno.1994.1332 7835792
4. The follow-up of ovarian cancer. Vaidya AP, Curtin JP, Semin Oncol 2003 30 401 412 10.1016/S0093-7754(03)00100-3 12870142 (Pubitemid 36706565)
5. Post-therapy surveillance and after-care in ovarian cancer. von Georgi R, Schubert K, Grant P, Munstedt K, Eur J Obstet Gynecol Reprod Biol 2004 114 228 233 10.1016/j.ejogrb.2003.10.029 15140520 (Pubitemid 38622087)
6. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Gadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E, Int J Gynecol Cancer 2007 17 21 31 10.1111/j.1525-1438. 2007.00826.x 17291227 (Pubitemid 46213965)
7. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Bast RC, Thigpen JT, Arbuck SG, et al. Gynecol Oncol 2007 107 173 176 10.1016/j.ygyno.2007.08.092 17950384 (Pubitemid 47575741)
8. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Goonewardene TI, Hall MR, Rustin GJ, Lancet Oncol 2007 8 813 821 10.1016/S1470-2045(07)70273-5 17765190 (Pubitemid 47308670)
9. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Alexandre J, Brown C, Coeffic D, et al. Br J Cancer 2012 106 633 637 10.1038/bjc.2011.593 22240800
10. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. Vergote I, Rustin GJ, Eisenhauer EA, et al. J Natl Cancer Inst 2000 92 1534 1535 10.1093/jnci/92.18. 1534 10995813
11. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE, Ann Oncol 1996 7 361 364 10.1093/oxfordjournals.annonc.a010602 8805927 (Pubitemid 26246787)
12. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T, J Clin Oncol 2001 19 4054 4057 11600607 (Pubitemid 32976692)
13. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Rustin GJ, van der Burg ME, Griffin CL, et al. Lancet 2010 376 1155 1163 10.1016/S0140-6736(10)61268-8 20888993
14. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Bristow RE, Puri I, Chi DS, Gynecol Oncol 2009 112 265 274 10.1016/j.ygyno.2008. 08.033 18937969
15. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Harter P, du Bois A, Hahmann M, et al. Ann Surg Oncol 2006 13 1702 1710 10.1245/s10434-006-9058-0 17009163 (Pubitemid 44951480)
16. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Harter P, Hahmann M, Lueck HJ, et al. Ann Surg Oncol 2009 16 1324 1330 10.1245/s10434-009-0357-0 19225844
17. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. van der Burg ME, Lammes FB, Verweij J, Ann Oncol 1990 1 301 302 2265140 (Pubitemid 20377102)
18. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. Wahl RL, Jacene H, Kasamon Y, Lodge MA, J Nucl Med 2009 50 Suppl 1 122S 150S 19403881
19. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. Kim CK, Park BK, Choi JY, Kim BG, Han H, J Comput Assist Tomogr 2007 31 868 875 10.1097/rct.0b013e31803e8c45 18043348 (Pubitemid 350196929)
20. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Gu P, Pan LL, Wu SQ, Sun L, Huang G, Eur J Radiol 2009 71 164 174 10.1016/j.ejrad.2008.02.019 18378417
21. The effect of measuring error on the results of therapeutic trials in advanced cancer. Moertel CG, Hanley JA, Cancer 1976 38 388 394 10.1002/1097-0142(197607)38:1<388::AID-CNCR2820380156>3.0.CO;2-A 947531
22. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Therasse P, Arbuck SG, Eisenhauer EA, et al. J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
23. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eisenhauer EA, Therasse P, Bogaerts J, et al. Eur J Cancer 2009 45 228 247 10.1016/j.ejca.2008.10.026 19097774
24. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG, Gynecol Oncol 1998 70 2 12 10.1006/gyno.1998.5051 9698465 (Pubitemid 28368866)
25. Toward the development of a universal grading system for ovarian epithelial carcinoma. Silverberg SG, Gynecol Oncol 1999 73 170 171 10.1006/gyno.1998.5328 10094903
26. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH, Int J Gynaecol Obstet 1999 65 243 249 10.1016/S0020-7292(99)00070-3 10428343 (Pubitemid 29281577)
27. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? Cannistra SA, J Clin Oncol 2002 20 1158 1160 11870154 (Pubitemid 34177418)
28. Recurrent ovarian cancer: evidence-based treatment. Ozols RF, J Clin Oncol 2002 20 1161 1163 11870155 (Pubitemid 34177419)
29. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Eisenhauer EA, Vermorken JB, van Glabbeke M, Ann Oncol 1997 8 963 968 10.1023/A:1008240421028 9402168 (Pubitemid 27475726)
30. Re: "clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation" Menczer J, Gynecol Oncol 2005 96 906 907 author reply 907 15721451
31. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Armstrong DK, Oncologist 2002 7 Suppl 5 20 28 12454316
32. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Fleming ND, Cass I, Walsh CS, Karlan BY, Li AJ, Gynecol Oncol 2011 121 249 252 10.1016/j.ygyno.2011.01.014 21300398
33. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE, Gynecol Oncol 2010 117 336 340 10.1016/j.ygyno.2010.01. 014 20153027
34. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. Frederick PJ, Ramirez PT, McQuinn L, et al. Int J Gynecol Cancer 2011 21 831 836 10.1097/IGC.0b013e31821743f9 21613957
35. Staging of advanced ovarian cancer: comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ, Radiology 2000 215 761 767 11037497 (Pubitemid 30346013)
36. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH, J Clin Oncol 2004 22 4051 4058 10.1200/JCO.2004.10. 028 15364966 (Pubitemid 41199651)
37. Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Francais d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer. Thiesse P, Ollivier L, Di Stefano-Louineau D, et al. J Clin Oncol 1997 15 3507 3514 9396404